Topical corticosteroids are the most common treatment for psoriasis. Fluocinolone acetonide is a medium potency corticosteroid that can reduce adverse effects from high potency steroids used. However, the thicken and hard skin from the hyperproliferation of the skin can block the entrance of a topical agent into the lesion site. The use of laser may be able to increase the transdermal absorption of topical fluocinolone acetonide for the treatment of scalp psoriasis. This study aimed to evaluate the efficacy of topical 0.1% fluocinolone acetonide gel in combination with a fractional Erbium YAG laser compare to topical 0.1% fluocinolone acetonide alone for the treating of scalp psoriasis. A 3-week, pilot study was conducted on 13 volunteers. Patients with psoriasis with at least mild severity, aged >18 years were enrolled. They were treated with fractional Erbium YAG laser and topical 0.1% fluocinolone acetonide gel applied once daily on the same site of lesion compare with received topical 0.1% fluocinolone acetonide gel alone apply once daily on another site of the lesion. The patients were followed up for 1 week to evaluate clinical symptoms by a physician and patient outcome measurement. Thirteen participants with a mean (SD) age of 52 years and at least mild severity were enrolled in the study. Compared to baseline, lesions were significantly improved in erythema, induration, and desquamation from the combination treatment and fluocinolone acetonide monotherapy although there were no statistically significant differences. Combining 0.1% fluocinolone acetonide and 0.1% fluocinolone acetonide with fractional Erbium YAG laser is an effective and safe treatment option for patients with scalp psoriasis. No statistically significant difference between the two groups. This study can assume that the use of 0.1% fluocinolone acetonide only has good affinity and penetration enough in the treatment of scalp psoriasis.